APG-115 in Salivary Gland Cancer Trial

  • Interventional
  • Recruiting
  • NCT03781986
Eligibility Details Visit Clinicaltrials.gov

A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

The current single arm study design was originally part of a study with a parallel arm given combination APG-115 + Carboplatin. In the initial phase of that previous iteration, the combination arm was closed early for issues related to tolerability of the combination therapy. This study will continue as a single arm, monotherapy alone, Phase I/II study as approved by the UM Institutional Review Board as of June 2021.


Age Group
18 Years and up

Accepting Healthy Volunteers?

Inclusion Criteria:

         - Histologically documented malignant salivary gland cancers (including secretory glands of the aerodigestive tract) with or without metastases, not amenable to curative treatment; or there is documentation of patient refusal of curative treatment.

         - Previous mutational testing with no evidence of a p53 mutation

         - Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

         - Presence of measurable disease by CT scan per RECIST v1.1 with ≥ 20% increase in tumor burden in the preceding 12 months

         - Life expectancy of ≥12 weeks

         - Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

         - Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

         - Patients must be able to take oral medication without breaking/opening, crushing, dissolving, or chewing capsules

         - Adequate organ and marrow function obtained ≤ 2 weeks prior to enrollment

        Exclusion Criteria:

         - Prior treatment with MDM2 inhibitors

         - Patients are not eligible if they have received any systemic anti-cancer therapy (including chemotherapy and/or hormone therapy) for salivary gland cancer within 4 weeks of the start of study therapy

         - Patients are not eligible if they have received any of the following within 4 weeks of the start of study therapy: live vaccines, antiretroviral drugs

         - Progressive disease within 6 months of the last dose of platinum-based chemotherapy

         - Patients with active brain metastases are excluded because of unknown penetration into the central nervous system (CNS). A confirmatory scan for asymptomatic patients is not required. Patients with a history of treated CNS metastases are eligible provided they meet all of the following criteria: disease outside the CNS is present, no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and enrollment, and recovery from significant (Grade ≥ 3) acute toxicity.

         - A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment

         - Patients (male and female) having procreative potential who are not willing or not able to use 2 adequate methods of contraception or practicing abstinence during the study and for 90 days following their last dose of treatment

         - Women who are pregnant or breast-feeding

At a Glance

National Government IDNCT03781986


Lead SponsorUniversity of Michigan Rogel Cancer Center

Lead PhysicianAlexander Pearson


18 Years and up